Frequency of Interferon-γ-Producing T Cells Specific for Trypanosoma cruzi Inversely Correlates with Disease Severity in Chronic Human Chagas Disease

This study sought to quantify CD8+ T cell responses to Trypanosoma cruzi and to identify potential links between these responses and the severity of disease in humans. In the majority of patients with Chagas disease, staining with class I major histocompatibility complex tetramers and analysis of in...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of infectious diseases Vol. 189; no. 5; pp. 909 - 918
Main Authors: Laucella, Susana A., Postan, Miriam, Martin, Diana, Fralish, Bolyn Hubby, Albareda, Maria C., Alvarez, Maria G., Lococo, Bruno, Barbieri, Gustavo, Viotti, Rodolfo J., Tarleton, Rick L.
Format: Journal Article
Language:English
Published: Chicago, IL The University of Chicago Press 01-03-2004
University of Chicago Press
Oxford University Press
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This study sought to quantify CD8+ T cell responses to Trypanosoma cruzi and to identify potential links between these responses and the severity of disease in humans. In the majority of patients with Chagas disease, staining with class I major histocompatibility complex tetramers and analysis of interferon (IFN)-γ ELISPOT responses to a panel of known cytotoxic T lymphocyte target epitopes from T. cruzi failed to identify parasitespecific CD8+ T cells. However, the frequency of individuals with positive ELISPOT responses was higher in areas of active transmission. Analysis of IFN-γ ELISPOT responses to a parasite lysate revealed a very high frequency of responders among patients with mild clinical disease and a very low frequency of responders among those with the most severe form of the disease. These data suggest that the frequency of IFN-γ- producing T cells in patients with chronic Chagas disease is associated with the history of recent exposure and with the clinical status of the patient.
Bibliography:Present affiliation: AlphaVax, Inc., Research Triangle Park, North Carolina.
istex:75BF2878C94F123B9856128BFFF16BF5333C57AE
ark:/67375/HXZ-425BSR39-4
ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ObjectType-Article-1
ObjectType-Feature-2
ISSN:0022-1899
1537-6613
DOI:10.1086/381682